# Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.

> **NCT05576779** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 2101 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **OTHER:** Ofatunumab

## Key facts

- **NCT ID:** NCT05576779
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-03
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 2101 (ACTUAL)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05576779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05576779, "Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05576779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*